It's that time of year when Wall Street analysts start adjusting their predictions, and one dividend-paying stock, in particular, is getting a lot of positive attention. Abbott Laboratories (NYSE: ABT) reported fourth-quarter earnings on Thursday, Jan. 26. Since then, Sanford C. Bernstein, Raymond James, Stifel Nicolaus, and Barclays have all raised their price targets on the healthcare conglomerate.
Abbott Laboratories ( NYSE:ABT ) Full Year 2022 Results Key Financial Results Revenue: US$43.7b (up 1.3% from FY 2021...
While the top- and bottom-line numbers for Abbott (ABT) give a sense of how the business performed in the quarter ended December 2022, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.